Clinical Trials
- Head and Neck Cancers, Phase 1 Cancers, Stomach and Esophagus, Thyroid and Other Endocrine Cancers
A Phase 1, First-in-Human, Open-Label, Dose Escalation and Expansion Study of CUE-101 Monotherapy in Patients With HPV+ Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
- Ages18 years and older
- GenderBoth
- Date06/19/2020
- Bladder Cancer, Breast Cancer, Colorectal Cancer, Head and Neck Cancers, Kidney Cancer, Leukemia, Liver Cancer, Lung Cancer, Melanoma, Pancreatic Cancer, Phase 1 Cancers, Prostate Cancer, Stomach and Esophagus, Thyroid and Other Endocrine Cancers, Lymphoma
A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
- Date06/11/2021
- Cancer, Gynecological Cancers, Head and Neck Cancers, Lung Cancer, Sarcoma Cancers
A Phase 2 Open Label Study of Sacituzumab Govitecan (IMMU-132) in Subjects With Metastatic Solid Tumors
- Date08/23/2021
- Head and Neck Cancers
A Phase 2, Randomized, Open-label Three-arm Clinical Study to Evaluate the Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) That Have Progressed After Platinum Therapy and Immunotherapy (PD-1/PD-L1 Inhibitors) (LEAP-009)
- Date05/25/2021
- Head and Neck Cancers
A Phase I Study of M6620 (VX-970) in Combination With Cisplatin and XRT in Patients With Locally Advanced HPV (-) Head and Neck Squamous Cell Carcinoma (HNSCC; SDC 10060121)
- Date09/30/2020
- Bladder Cancer, Breast Cancer, Colorectal Cancer, Gynecological Cancers, Head and Neck Cancers, Kidney Cancer, Lung Cancer, Melanoma, Phase 1 Cancers, Stomach and Esophagus
A Phase Ia/Ib Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of MTIG7192A as a Single Agent and in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Tumors
- Ages18 years and older
- GenderBoth
- Date06/25/2020
- Head and Neck Cancers, Stomach and Esophagus
A Phase II/III Randomized Study of Maintenance Nivolumab Versus Observation in Patients With Locally Advanced, Intermediate Risk HPV Positive OPCA
- Date07/15/2020
- Bladder Cancer, Breast Cancer, Colorectal Cancer, Gynecological Cancers, Head and Neck Cancers, Kidney Cancer, Liver Cancer, Lung Cancer, Melanoma, Other Cancers, Pancreatic Cancer, Pediatric Cancers, Prostate Cancer, Sarcoma Cancers, Stomach and Esophagus, Thyroid and Other Endocrine Cancers
A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating With Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864) in Patients With Intermediate Risk (IR) Rhabdomyosarcoma (RMS)
- Date06/23/2021
- Head and Neck Cancers, Other Cancers, Sarcoma Cancers
A Randomized, Controlled, Open-Label, Phase 2 Study of Cemiplimab as a Single Agent and in Combination With RP1 in Patients With Advanced Cutaneous Squamous Cell Carcinoma
- Ages18 years and older
- GenderBoth
- Date02/25/2021
- Bladder Cancer, Breast Cancer, Cancer, Colorectal Cancer, Gynecological Cancers, Head and Neck Cancers, Kidney Cancer, Liver Cancer, Lung Cancer, Melanoma, Other Cancers, Pancreatic Cancer, Phase 1 Cancers, Prostate Cancer, Sarcoma Cancers, Stomach and Esophagus, Thyroid and Other Endocrine Cancers
An Open-Label, Randomized-Sequence, Multicenter, Single-Crossover Study to Assess the Relative Bioavailability of Niraparib Tablet Formulation Compared to Niraparib Capsule Formulation in Patients With Advanced Solid Tumors
- Date05/09/2021